JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

Search

Microbot Medical Inc

Gesloten

2.65 -8.3

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.64

Max

2.96

Belangrijke statistieken

By Trading Economics

Inkomsten

791K

-2.6M

Werknemers

20

EBITDA

-127K

-3.4M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+210.34% upside

Dividenden

By Dow Jones

Volgende Winsten

12 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

23M

115M

Vorige openingsprijs

10.95

Vorige sluitingsprijs

2.65

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

Microbot Medical Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 jul 2025, 23:57 UTC

Acquisities, Fusies, Overnames

EQT: To Spend Y407.82B for Tender Offer

29 jul 2025, 23:56 UTC

Acquisities, Fusies, Overnames

EQT: Tender Offer Price Is Y5,700 a Share

29 jul 2025, 23:54 UTC

Acquisities, Fusies, Overnames

EQT To Start Tender Offer for Fujitec

29 jul 2025, 23:50 UTC

Marktinformatie

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 jul 2025, 23:36 UTC

Marktinformatie

Gold Steady Ahead of FOMC Decision -- Market Talk

29 jul 2025, 22:57 UTC

Marktinformatie

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 jul 2025, 22:50 UTC

Marktinformatie

Mondelez Warns of Price Increases in North America -- Market Talk

29 jul 2025, 22:44 UTC

Acquisities, Fusies, Overnames

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 jul 2025, 22:41 UTC

Acquisities, Fusies, Overnames

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 jul 2025, 22:41 UTC

Acquisities, Fusies, Overnames

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 jul 2025, 22:35 UTC

Winsten

IGO Maintains Nova Life of Mine Production Guidance

29 jul 2025, 22:35 UTC

Winsten

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 jul 2025, 22:35 UTC

Winsten

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 jul 2025, 22:34 UTC

Winsten

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 jul 2025, 22:34 UTC

Winsten

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 jul 2025, 22:34 UTC

Marktinformatie
Winsten

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 jul 2025, 22:33 UTC

Winsten

IGO Had A$279.7 Million of Cash at End-June

29 jul 2025, 22:33 UTC

Winsten

IGO 4Q Underlying Free Cash A$2.4 Million

29 jul 2025, 22:33 UTC

Winsten

IGO FY Sales Revenue A$512.5 Million

29 jul 2025, 22:33 UTC

Winsten

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 jul 2025, 22:32 UTC

Winsten

IGO FY Nickel Production 17,173 Tons

29 jul 2025, 22:32 UTC

Winsten

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 jul 2025, 22:32 UTC

Winsten

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 jul 2025, 22:31 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

29 jul 2025, 22:31 UTC

Marktinformatie
Winsten

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 jul 2025, 22:31 UTC

Winsten

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 jul 2025, 22:31 UTC

Winsten

IGO FY Spodumene Production 1.48 Million Tons

29 jul 2025, 22:30 UTC

Winsten

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 jul 2025, 22:30 UTC

Winsten

IGO 4Q Underlying Ebitda A$62 Million

29 jul 2025, 22:22 UTC

Winsten

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Peer Vergelijking

Prijswijziging

Microbot Medical Inc Prognose

Koersdoel

By TipRanks

210.34% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 9 USD  210.34%

Hoogste 9 USD

Laagste 9 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Microbot Medical Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technische score

By Trading Central

2.52 / 2.57Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Very Strong Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.